CN119173253A - 用于治疗癌症的变构和正构egfr抑制剂的组合产品 - Google Patents

用于治疗癌症的变构和正构egfr抑制剂的组合产品 Download PDF

Info

Publication number
CN119173253A
CN119173253A CN202380039827.0A CN202380039827A CN119173253A CN 119173253 A CN119173253 A CN 119173253A CN 202380039827 A CN202380039827 A CN 202380039827A CN 119173253 A CN119173253 A CN 119173253A
Authority
CN
China
Prior art keywords
combination
methyl
indazol
egfr inhibitor
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202380039827.0A
Other languages
English (en)
Chinese (zh)
Inventor
G·耶施克
B·马尔托利奥
Y·A·纳吉尔
C·U·奥布斯特-桑德尔
A·里奇
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Publication of CN119173253A publication Critical patent/CN119173253A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN202380039827.0A 2022-05-13 2023-05-11 用于治疗癌症的变构和正构egfr抑制剂的组合产品 Pending CN119173253A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP22173211.8 2022-05-13
EP22173211 2022-05-13
EP22175302 2022-05-25
EP22175302.3 2022-05-25
PCT/EP2023/062530 WO2023217924A1 (en) 2022-05-13 2023-05-11 Combination of allosteric and orthosteric egfr inhibitors for the treatment of cancer

Publications (1)

Publication Number Publication Date
CN119173253A true CN119173253A (zh) 2024-12-20

Family

ID=86558741

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202380039827.0A Pending CN119173253A (zh) 2022-05-13 2023-05-11 用于治疗癌症的变构和正构egfr抑制剂的组合产品

Country Status (9)

Country Link
US (1) US20260007678A1 (enExample)
EP (1) EP4522113A1 (enExample)
JP (1) JP2025516543A (enExample)
KR (1) KR20250009977A (enExample)
CN (1) CN119173253A (enExample)
AU (1) AU2023268579A1 (enExample)
CA (1) CA3255503A1 (enExample)
TW (1) TW202408534A (enExample)
WO (1) WO2023217924A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020254565A1 (en) 2019-06-21 2020-12-24 F. Hoffmann-La Roche Ag Egfr inhibitors for the treatment of cancer
WO2022117475A1 (en) 2020-12-01 2022-06-09 F. Hoffmann-La Roche Ag New indazole derivatives

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020254565A1 (en) * 2019-06-21 2020-12-24 F. Hoffmann-La Roche Ag Egfr inhibitors for the treatment of cancer
WO2022117487A1 (en) * 2020-12-01 2022-06-09 F. Hoffmann-La Roche Ag New indazole derivatives
US20240002390A1 (en) * 2020-12-01 2024-01-04 Hoffmann-La Roche Inc. New indazole acetylene derivatives
WO2022117475A1 (en) * 2020-12-01 2022-06-09 F. Hoffmann-La Roche Ag New indazole derivatives

Also Published As

Publication number Publication date
TW202408534A (zh) 2024-03-01
EP4522113A1 (en) 2025-03-19
US20260007678A1 (en) 2026-01-08
AU2023268579A1 (en) 2024-09-19
CA3255503A1 (en) 2023-11-16
JP2025516543A (ja) 2025-05-30
WO2023217924A1 (en) 2023-11-16
KR20250009977A (ko) 2025-01-20

Similar Documents

Publication Publication Date Title
JP7530391B2 (ja) がんの治療のためのｅｇｆｒ阻害剤
CN114025844B (zh) 蛋白酪氨酸磷酸酶抑制剂及其使用方法
EP4667458A1 (en) Pharmaceutical composition for treatment of cancer, comprising sos1 inhibitor and anticancer drug
CN113993591A (zh) 新egfr抑制剂
EP4483881A2 (en) Fused ring compounds
CN112955438A (zh) 蛋白质酪氨酸磷酸酶抑制剂和其使用方法
AU2016385839A1 (en) Quinolin-2-one derivatives
EP4076665B1 (en) Egfr inhibitors
BR112020008122B1 (pt) Derivados de pirazolo-pirrolo-pirimidina-diona como inibidores de p2x3, seu uso, e composição farmacêutica
TW202408534A (zh) 用於治療癌症的別位及正位ｅｇｆｒ抑制劑之組合
KR20220118426A (ko) Egfr 억제제
CN113993589A (zh) 新egfr抑制剂
BR112021014466A2 (pt) Derivados de indazolil-isoxazol para o tratamento de doenças, tal como câncer
JP2023550902A (ja) 新規インダゾールアセチレン誘導体
ES2927480T3 (es) Compuestos de isoindolina-acetileno para el tratamiento del cáncer
HK40115468A (zh) 用於治疗癌症的变构和正构egfr抑制剂的组合产品
RU2853003C1 (ru) Новые индазолацетиленовые производные
RU2799446C2 (ru) Ингибиторы протеин-тирозинфосфатазы и способы их применения
RU2818677C2 (ru) Ингибитор egfr для лечения рака
HK40063822A (en) Egfr inhibitor for the treatment of cancer
HK40071776A (en) Egfr inhibitors
HK40094041A (zh) 新的吲唑乙炔衍生物

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40115468

Country of ref document: HK

SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination